Zafari Zangeneh Farideh, Naghizadeh Mohammad Mehdi, Jafarabadi Mina, Dehghan Masoumeh, Bagheri Maryam
Vali-E-Asr Reproductive Health Research Center, Family Health Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Non-communicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.
J Family Reprod Health. 2025 Jun;19(2):111-121. doi: 10.18502/jfrh.v19i2.19299.
Building upon prior research, our investigation focused on examining changes in gene expression of Connexins 37 and 43 (Cx) influenced by β2-adrenergic agents in cumulus cell cultures from women with polycystic ovarian syndrome (PCOS) and poor ovarian response (POR), all of whom were candidates for in vitro fertilization (IVF).
This experimental study was conducted between April 2021 and November 2023, involving three groups: a control group (donated eggs) and two study groups (POR and PCO). All three groups received ovulation stimulation drugs. Following oocyte puncture, cumulus cells (CCs) were isolated and placed in a culture medium. After three passages, CCs were exposed to the ADR-β2 agonist isoproterenol and its antagonist propranolol (100nM for both drugs). RNA extraction was performed, and cDNA was synthesized. Real-time PCR was used to determine gene expression, and protein levels were measured through the Western blotting method.
The gene expression of Cx 37/43 was significantly reduced in all three groups (P<0.001). For women with PCO and POR, Isop notably decreased expressions (P<0.001), while Prop increased them (P<0.001). Western Blot results confirmed these findings.
The findings of this in-vitro study suggest that the beta-2 adrenergic antagonist propranolol could upregulate gene expression of Cx37/43 in the cellular connections of CCs among infertile women. Consequently, propranolol may enhance communication between CCs and oocytes, facilitating the transfer of signalling messengers and other essential agents required for oocyte development. This novel discovery could have significant implications for oocyte growth and maturation, offering valuable perspectives on drug treatment and assisted reproductive technology. This novel discovery could have significant implications for oocyte growth and maturation, offering valuable perspectives on drug treatment and assisted reproductive technology.
基于先前的研究,我们的调查聚焦于研究多囊卵巢综合征(PCOS)和卵巢反应不良(POR)的女性卵丘细胞培养物中,β2 - 肾上腺素能药物对连接蛋白37和43(Cx)基因表达的影响,这些女性均为体外受精(IVF)的候选者。
本实验研究于2021年4月至2023年11月进行,涉及三组:对照组(捐赠卵子)和两个研究组(POR组和PCO组)。所有三组均接受排卵刺激药物。卵母细胞穿刺后,分离卵丘细胞(CCs)并置于培养基中。传代三次后,将CCs暴露于ADR - β2激动剂异丙肾上腺素及其拮抗剂普萘洛尔(两种药物均为100nM)。进行RNA提取并合成cDNA。使用实时PCR测定基因表达,并通过蛋白质印迹法测量蛋白质水平。
所有三组中Cx 37/43的基因表达均显著降低(P<0.001)。对于PCO和POR女性,异丙肾上腺素显著降低表达(P<0.001),而普萘洛尔则使其增加(P<0.001)。蛋白质印迹结果证实了这些发现。
这项体外研究的结果表明,β2 - 肾上腺素能拮抗剂普萘洛尔可上调不育女性CCs细胞连接中Cx37/43的基因表达。因此,普萘洛尔可能增强CCs与卵母细胞之间的通讯,促进信号信使和卵母细胞发育所需的其他重要因子的传递。这一新发现可能对卵母细胞的生长和成熟具有重要意义,为药物治疗和辅助生殖技术提供有价值的观点。这一新发现可能对卵母细胞的生长和成熟具有重要意义,为药物治疗和辅助生殖技术提供有价值的观点。